NIH-supported research has identified a type of immune cell that helps remove waste products in the brain. Boosting these immune cells in aged mice improved the clearance of proteins associated with Alzheimer’s disease. The findings suggest potential prevention and treatment strategies for Alzheimer’s disease and related disorders.
Researchers have discovered two novel genes that increase an individual’s risk of developing Alzheimer’s disease. The researchers used a technique called exome sequencing to identify the genes. Exome sequencing is able to identify rare mutations. The discovery brings scientists closer to finding treatment options and preventative measures for the disease.
With the new approved drug for Alzheimer’s there is now the issue of what it will cost and how you’ll be able to afford it.
Biogen said the drug would cost approximately $56,000 for a typical year’s worth of treatment, and it said the price would not be raised for four years.
Medicare is widely expected to cover the treatment. Insurers that offer private or commercial coverage also will pay for care that doctors deem medically necessary.
That may not mean every case, though. If the treatment is proposed for a patient with advanced Alzheimer’s, and research shows the drug isn’t effective in that population, then the insurer may not pay for it.